Compare ROIV & AXIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROIV | AXIA |
|---|---|---|
| Founded | 2014 | 1962 |
| Country | United Kingdom | Brazil |
| Employees | N/A | 7168 |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0B | 21.9B |
| IPO Year | 2021 | N/A |
| Metric | ROIV | AXIA |
|---|---|---|
| Price | $30.28 | $10.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $28.94 | N/A |
| AVG Volume (30 Days) | ★ 5.9M | 2.0M |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 6.68% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,260,000.00 | N/A |
| Revenue This Year | N/A | $15.92 |
| Revenue Next Year | $744.61 | $7.32 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.71 | $8.78 |
| 52 Week High | $32.79 | $13.54 |
| Indicator | ROIV | AXIA |
|---|---|---|
| Relative Strength Index (RSI) | 56.52 | 42.16 |
| Support Level | $27.44 | $9.17 |
| Resistance Level | $32.79 | $12.16 |
| Average True Range (ATR) | 0.87 | 0.23 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 86.99 | 54.44 |
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Axia Energia is engaged in the generation, transmission, and commercialization of electricity in Brazil. The company operates a portfolio of wind, thermal, hydro, and nuclear power plants located throughout the country.